Company Overview
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.
Why Investors Should Care
Revenue has grown at a 25.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.55M (-0.2% YoY); net profit $-18.18M.
- Trailing 12 Months Year-on-year growth — revenue -51.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 25.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 25.88% |
| 1 Year: | -51.60% |
Stock Price Performance
| 1 Year: | -38.06% |
| 6 Months: | -81.52% |
| 3 Months: | -54.85% |
| 1 Month: | -10.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 25.9% over 5 years.
CONS
- Trading 96.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FEED ENvue Medical, Inc. PHARMA | 4.28 | -0.01 | $3.95M | 0.00% | -66.41% | -59.14% | 25.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.00K | - | 101.00K | 114.00K | 269.00K | 150.00K | 103.00K | 318.00K | 499.00K | 272.00K | 485.00K | 97.00K | 354.00K | 294.00K | 458.00K | 921.00K | 817.00K | 376.00K | 1.02M | 494.00K | 722.00K | 653.00K |
| Gross Profit | -40.00K | 39.00K | -10.00K | 19.00K | 24.00K | 30.00K | 30.00K | 40.00K | 34.00K | 36.00K | 34.00K | 43.00K | 55.00K | 77.00K | 8.00K | 53.00K | 207.00K | 47.00K | 51.00K | 38.00K | 99.00K | 77.00K | 208.00K | 228.00K | 106.00K | 281.00K | 80.00K | 235.00K | 216.00K | 349.00K | 664.00K | 428.00K | 133.00K | 369.00K | -35.00K | 189.00K | -55.00K |
| Operating Income | 144.00K | -268.00K | -518.00K | -311.00K | -315.00K | -338.00K | -474.00K | -456.00K | -545.00K | -802.00K | -660.00K | -613.00K | -790.00K | -825.00K | -1.33M | -2.22M | -896.00K | -793.00K | -907.00K | -1.47M | -804.00K | -1.31M | -991.00K | -868.00K | -1.11M | -1.27M | -924.00K | -1.05M | -1.01M | -670.00K | -568.00K | -674.00K | -970.00K | -1.85M | -3.98M | -2.25M | -3.71M |
| Net Income | -503.00K | -578.00K | -766.00K | -630.00K | -434.00K | -1.04M | -495.00K | -610.00K | -606.00K | -877.00K | -849.00K | -1.60M | -789.00K | -824.00K | -1.34M | -2.68M | -1.11M | -815.00K | -921.00K | -1.48M | -922.00K | -4.92M | -216.00K | -6.67M | -1.13M | -1.30M | -955.00K | -1.10M | -1.07M | -727.00K | -588.00K | -688.00K | -998.00K | -1.87M | -3.97M | 510.00K | -3.82M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.93 | -0.68 | -0.67 | -0.65 | -0.42 | 2.38 | -27.18 | -3.56 | -29.90 | -1.03 | -0.91 | -6.88 |
| R&D Expense | -90.00K | 89.00K | 101.00K | 95.00K | 115.00K | 87.00K | 114.00K | 173.00K | 161.00K | 150.00K | 164.00K | 160.00K | 136.00K | 151.00K | 121.00K | 152.00K | 150.00K | 79.00K | 47.00K | 16.00K | 68.00K | 64.00K | 64.00K | 50.00K | 66.00K | 61.00K | 49.00K | 55.00K | 35.00K | 33.00K | 121.00K | 187.00K | 249.00K | 530.00K | 972.00K | 221.00K | 468.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 203.00K | 147.00K | 229.00K | 239.00K | 318.00K | 530.00K | 623.00K | 1.70M | 752.00K | 2.28M | 2.56M | 2.55M |
| Gross Profit | 110.00K | 98.00K | 141.00K | 151.00K | 160.00K | 281.00K | 214.00K | 770.00K | 167.00K | 1.54M | 1.51M | 153.00K |
| Operating Income | -1.21M | -1.42M | -2.32M | -3.09M | -4.30M | -5.15M | -4.72M | -5.68M | -5.01M | -3.44M | -3.58M | -22.89M |
| Net Income | -2.65M | -2.88M | -2.83M | -4.96M | -4.15M | -5.79M | -4.33M | -14.28M | -5.45M | -3.71M | -3.71M | -18.18M |
| Diluted EPS | - | - | - | - | - | - | - | - | -3.84 | -23.32 | -137.30 | -26.69 |
| R&D Expense | 431.00K | 399.00K | 584.00K | 693.00K | 614.00K | 514.00K | 171.00K | 293.00K | 283.00K | 185.00K | 909.00K | 1.76M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 723.00K | 1.98M | 494.00K | 4.87M | 1.58M | 2.04M | 8.23M | 8.62M | 5.88M | 6.67M | 3.63M | 41.12M |
| Total Equity | -3.30M | -5.62M | -209.00K | -2.50M | 3.63M | 463.00K | 1.35M | 2.39M | 6.31M | 3.23M | 3.99M | 627.00K | 33.50M |
| Cash & Equivalents | 94.00K | 90.00K | 1.61M | 106.00K | 4.36M | 896.00K | 1.34M | 7.14M | 7.74M | - | - | 752.00K | 4.22M |
| Total Liabilities | - | - | - | - | - | 1.12M | 688.00K | 5.83M | 2.31M | 2.65M | 2.69M | 3.00M | 7.63M |
| Current Liabilities | - | 5.42M | 297.00K | 565.00K | 797.00K | 640.00K | 409.00K | 2.90M | 1.90M | 2.32M | 2.45M | 2.72M | 6.66M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -1.53M | -2.18M | -3.55M | -3.87M | -3.39M | -4.37M | -7.04M | -3.60M | -2.52M | -9.37M |
| Investing Cash Flow | - | - | -8.00K | - | -8.00K | - | -2.00K | -3.00K | -3.00K | -1.00K | -3.00K | 88.00K |
| Financing Cash Flow | - | - | 33.00K | 6.44M | 94.00K | 4.32M | 9.52M | 4.58M | 2.09M | 4.22M | 1.00K | 12.79M |
| Capital Expenditure | -4.00K | -1.00K | -8.00K | - | -8.00K | - | -2.00K | -3.00K | -3.00K | -1.00K | -3.00K | -60.00K |
| Free Cash Flow | - | - | -1.54M | - | -3.56M | - | -3.39M | -4.37M | -7.04M | -3.60M | -2.52M | -9.43M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 54.2% | 66.7% | 61.6% | 63.2% | 50.3% | 53.0% | 34.3% | 45.4% | 22.2% | 67.3% | 59.0% | 6.0% |
| Operating Margin % | -596.6% | -968.7% | -1,011.4% | -1,293.3% | -1,353.1% | -971.9% | -757.5% | -335.3% | -666.5% | -150.5% | -140.0% | -896.6% |
| Net Margin % | -1,303.9% | -1,961.9% | -1,236.2% | -2,077.4% | -1,306.3% | -1,093.2% | -694.4% | -842.6% | -724.5% | -162.5% | -144.8% | -712.3% |
| ROE % | 47.1% | 1,379.9% | 113.3% | -136.6% | -897.2% | -430.1% | -180.7% | -226.2% | -168.5% | -93.0% | -590.9% | -54.3% |
| ROCE % | 25.8% | -84.5% | 3,262.0% | -76.0% | -457.8% | -316.6% | -88.6% | -84.6% | -140.7% | -81.4% | -394.9% | -66.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 1.04% | 9.63K | $7.60K |
| 2 | Virtu Financial LLC | 0.86% | 7.94K | $6.26K |
| 3 | Jane Street Group, LLC | 0.34% | 3.14K | $2.47K |
| 4 | Geode Capital Management, LLC | 0.14% | 1.29K | $1.02K |
| 5 | Two Sigma Securities, LLC | 0.09% | 857 | $676 |
| 6 | Osaic Holdings Inc. | 0.09% | 833 | $657 |
| 7 | Tower Research Capital LLC (TRC) | 0.04% | 398 | $314 |
| 8 | Global Retirement Partners, LLC | 0.01% | 133 | $104 |
| 9 | Vanguard Capital Management LLC | - | 16 | $12 |
| 10 | Vanguard Fiduciary Trust Co | - | 7 | $5 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FEED
ENVUE MEDICAL INC (FEED) Stock Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE5leGlzbU0yQTM1V3ZxeVViLVZYdTVFRGdtN2VsaTBYbVlTbGFyRjEwa0l3ZFJOeDlBSmxnWG1VOTI1TUx1S1F0RWU3MEZZaXFwSzQtTTZjT25MNy0xUWNuTDZsOVQ?oc=5" target="_blank">ENVUE MEDICAL INC (FEED) Stock C…
Prop Industry Leader The5ers Brings Single Stock Futures via CME Feed - The Manila Times
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNWWRaXzB0ZmU2bTRFT1A3N09nWndPaEJ5Z0hJd0JEUzg3R0ZZb19HYUs3bUluNWhSVFRkUXpDdjRnNVRPcjVVN0Q0ZElsTGtkbkxMdmw1Z2k1TVNnVy1ZUUhYRFM0b0puTDBRcDhyMGtlQkwta3FMOWxhOHQ1U21tSnJ6UXNEaVhtQzlXQW…
ENvue Medical, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNTlZ6eWd1SFQzV0lURjV4UEN4S3R5VXVlc2lzaVJiWlMydGV4UWV1X1Bld0VMRUlGMG9TN0hueVUyZUJsVXhNTm5CX0x0b2UzeXRoMnJWRU5MTzlIdkJ0YV90YTRlVVdkMExTSTdxUGpKazU5ZkFpbFpydkFxel9LNTBlX2h1ck1jZV96TH…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFA4OTJydDJJV0ZXRkM0bVBMaTZlY1lSRnAxNDVaSHBlMVg2N1htTFp1amNZTWg4VG01bnFsRV9LX2ItbU82LUpmVWZWZUtXSTJt?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Investors Maxing Out AI Trade Feed Stock Market Volatility - Bloomberg.com
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOZU9GQ2tZM1hMUWRlU1VDNEVIMlZ2Y2JWUlBkVHBUN0U2MF9VTENMTjdYbVIzRXNxOXdQQlV5OE84ZnRQNEd6Y216OXF1c0NhRmRNY2RtdnR5UkR0M2dlby1oTDlrU1NMRDdHMmllRXVsendqQ0s3OFVpMk5makZSSlZPdURVTzR5bEVzSE…
Changing bacterial feedstock unlocks flexible biopolymers with stronger antibacterial effects - Phys.org
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNa19Rd2FkZWhJR1dTdm0ySkVBVlFyc2czd0sxSDhyT19JUkFNM3IzMzRlb0JHU3A2VzB1enZyNi1qSEFRNjNxd0ROVmtoN1QzT21LX0Q3Ujk0eFpjS3FnQUhRVGxJbkloRmJKZ3NKQUJQMmhaUkVNaVVQWlVhQXM0bE5XZW8xQnhOeWZzVA…
FEED — Frequently Asked Questions
What is the current share price of ENvue Medical, Inc. (FEED)?
As of 2026-09-19 21:16 PDT, ENvue Medical, Inc. (FEED) trades at $4.28 on NasdaqCM. Its 52-week range is $3.79 to $128.40.
What is the market capitalisation of FEED?
ENvue Medical, Inc. (FEED) has a market capitalisation of $3.95M on NasdaqCM.
What is the P/E ratio of FEED?
FEED trades at a trailing price-to-earnings (P/E) ratio of -0.01. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.42.
What is the return on equity (ROE) of FEED?
FEED has a return on equity (ROE) of -59.14%. Its return on capital employed (ROCE) is -66.41%.
Is FEED a good stock to buy?
This page provides a data-driven analysis of ENvue Medical, Inc. (FEED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.